Physician profile
Luann Elmore
NPI 1861408809
$510.14
in general payments reported to CMS, 2019-2025
13 companies · $192 in 2025
The $192 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $104 · 2022: $89.61 · 2023: $72.15 · 2024: $52.85 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $316.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $124.45 | 2025 | Sublocade |
| Biohaven Pharmaceuticals, INC. | $49.95 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.27 | 2022 | |
| Novo Nordisk INC | $43.63 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $41.36 | 2023 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $39.68 | 2024 | Voquezna |
| Lilly USA, LLC | $37.79 | 2021-2024 | Mounjaro, Zepbound |
| Biohaven Pharmaceutical Holding Company LTD. | $33.54 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $27.36 | 2022-2025 | Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.28 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.39 | 2021 | |
| Abbvie INC. | $15.07 | 2025 | |
| Amarin Pharma, INC. | $13.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luann Elmore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.